First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) β StellaPhase 2 β Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(1 site)
Japan
National Cancer Center Hospital, ChΕ«Ε, Tokyo Age range
18 Years and older
Last updated October 2023